Fluid Biospsy Market - Forecast(2025 - 2031)

Fluid Biopsy Market Overview

Fluid Biopsy market size is forecast to reach US$54.3 billion by 2030, after growing at a CAGR of 19.6% during 2024-2030. Liquid biopsy also known as fluid biopsy or fluid phase biopsy, a non-invasive fast technique, which helps to detect and diagnose a variety of cancers such as lung, liver, breast and others at an early stage. The going prevalence of cancer worldwide is the primary driver for the market growth. The non-invasive nature of procedures which reduce the risk of complications associated with surgical biopsies, growing cancer awareness programs by governments and investments in cancer hospitals and cancer research facilities are propelling the growth of Fluid Biopsy Market globally. 
While oncology remains a major driver, fluid biopsy is expanding into other areas like infectious diseases, genetic disorders, and autoimmune diseases. For instance, Fluid biopsy can be used to monitor viral load and track treatment response in diseases like HIV, hepatitis B, and hepatitis C. It can also be used for non-invasive prenatal testing (NIPT) to screen for fetal chromosomal abnormalities. By expanding its applications beyond oncology, the fluid biopsy market can tap into new patient populations and drive further growth. Additionally, the development of point-of-care testing (POCT) solutions for fluid biopsy is also a major trend driving the market growth by improving accessibility, reducing turnaround times, and enhancing patient care. 

Market Snapshot: 

Fluid Biopsy Market - Report Coverage:

The “Fluid Biopsy Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Fluid Biopsy Market.
 

COVID-19 / Ukraine Crisis - Impact Analysis:  

•    The COVID-19 pandemic disrupted clinical trials, leading to delays in the development and commercialization of new liquid biopsy tests. Healthcare spending was reduced due to the pandemic, leading to decreased investment in new technologies like liquid biopsy. 
•    The Russia-Ukraine conflict disrupted global supply chains, affecting the availability of critical reagents, chemicals, and equipment necessary for fluid biopsy research and development. The geopolitical tensions and economic sanctions resulting from the conflict have created uncertainty in the global economy, potentially leading to reduced investments in healthcare, including fluid biopsy.

Key Takeaways

Breast Cancer is the Largest Segment 

Breast cancer cases are leading in the fluid biopsy market, in terms of cancer segment. Breast cancer is a highly heterogeneous disease. The treatment of breast cancer is complicated owing to intratumoral complexity. Fluid biopsies are being widely used as a way to improve early detection of cancer, monitor disease progression, and help guide treatment decisions. For instance, according to American Cancer Society’s Breast Cancer Facts & Figures 2024-2025, In 2024 an estimated 310,720 new invasive breast cancers and 56500 cases of ductal carcinoma in situ will be diagnosed among women in the US, and additional 2790 cases will be diagnosed in men. Additionally, 42,250 women and 530 men in US are expected to die from breast cancer in 2024. Thus, the rising prevalence of breast cancer cases is fueling the fluid biopsy market globally. 

Circulating Tumor DNA (ctDNA) is leading the Market 
The Circulating Tumor DNA (ctDNA) segment holds the largest share in the fluid biopsy market. Using ctDNA-based liquid biopsy offers a number of benefits, such as non-invasive or minimally invasive collection techniques, the ability to do several assessments, and thorough understanding of tumor biology. By enabling the screening of high-risk patients, dynamically monitoring therapy responses, and diagnosing, it plays vital roles in disease management. It is also possible to monitor postoperative tumor status, show pseudo-progression, and direct adaptive therapy strategies using ctDNA. Through the mechanism of apoptosis, necrosis, and circulating exosome release in tumor cells, ctDNA can spread throughout the circulatory system and carry modifications such as methylations, mutations, gene rearrangements, and microsatellite instability. For instance, The Lancet’s commission on prostate cancer, published in April 2024, forecasts the number of new cases of prostate cancer to increase annually worldwide from 1.4 million in 2020, to 2.9 million by 2040, and the number of deaths worldwide is predicted to rise from 375 000 in 2020, to almost 700 000 by 2040. By analyzing changes in ctDNA mutations, doctors can identify when a tumor is becoming resistant to therapy, enabling a switch to more effective treatments.

North America Leads the Market
North America dominated the Fluid Biopsy market with a market share of up to 37% in 2023 due to rising cancer cases in this region and along with rising research and developments. According to American Cancer Society, nearly 2 million cases are projected in 2024 which equates to almost 5,500 cancer diagnoses a day. In 2024, over 6,11,000 deaths from cancer are projected for the US equivalent to more than 1,600 deaths from cancer each day. The growing R&D on cancer research in countries like USA is propelling the market growth in this region. For instance, according to American Association for Cancer Research’s Cancer Progress Report, Among the advances made between July 1, 2023, and June 30, 2024, are the 15 new anticancer therapeutics approved for use by FDA. During the same period, FDA also approved a new imaging agent to aid breast cancer surgery and expanded the use of 15 previously approved anticancer therapeutics to treat additional cancer types. Such factors are fuelling the growth of Fluid Biopsy Market in this region. 

Rising Cancer Incidence Drives the Market
The rising global cancer incidence is a major driver behind the expansion of the fluid biopsy market. Cancer continues to be a major health concern worldwide, with a mounting number of new cases diagnosed each year. For instance, according to the World Health Organisation, globally over 35 million new cancer cases are predicted in 2050, an increase from the estimated 20 million in 2022. With millions of new cancer cases diagnosed annually the demand for effective diagnostic tests options continues to escalate. A report by Cancer Research UK states that by 2040 there are projected to be 500,000 new cancer cases diagnosed each year in the UK attributed to a growing and ageing population. Fluid biopsy, characterized by its non-invasive nature and ability to detect cancer-related biomarkers in bodily fluids like blood or urine, has emerged as a game-changing solution in the fight against cancer. Thus, the increasing prevalence of cancer worldwide is fueling the growth of the global fluid biopsy market. 

High Prices to Hamper Growth
One of the key challenges in the Fluid Biopsy market is the high initial cost of fluid biopsy treatments. Fluid biopsy often relies on highly sensitive techniques like next-generation sequencing (NGS) to detect minute amounts of circulating tumor DNA (ctDNA) in blood samples. The advanced equipment required for these procedures are expensive. For instance, according to a journal from National Library of Medicine, the Liquid Biopsy and Tissue Testing approach was more costly and incremental cost was $6203 and $4660, respectively. Additionally, several clinical trials are essential to validate the efficacy and safety of liquid biopsy tests, and these trials can be costly. 
 

Fluid Biopsy Market Key Players

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Fluid Biopsy Market. The top 10 players in the market are 
1.    Guardant Health
2.    Illumina
3.    Thermo Fisher Scientifc
4.    QIAGEN 
5.    Myriad genetics
6.    F. Hoffmann-La Roche AG
7.    Angle plc
8.    Ocimmune 
9.    Sysmex Corporation
10.    Bio-Rad Laboratories 

Scope of the Report: 
 

Relevant Reports 

Breast Biopsy Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 23527

Prostate Biopsy Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 68320  

Cancer Diagnostics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0195